BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15761376)

  • 21. [The signal transduction pathway of multi-target kinase inhibitors as anticancer agents in clinical use or in phase III].
    Wu W; Lu C; Chen SY; Yu NF
    Yao Xue Xue Bao; 2009 Mar; 44(3):242-57. PubMed ID: 19449520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New therapeutic approaches in glioblastomas].
    Le Guilloux J; Carpentier AF
    Rev Neurol (Paris); 2008; 164(6-7):554-9. PubMed ID: 18565354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of proteasome inhibitor action and resistance in cancer.
    McConkey DJ; Zhu K
    Drug Resist Updat; 2008; 11(4-5):164-79. PubMed ID: 18818117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular signal transduction pathway proteins as targets for cancer therapy.
    Adjei AA; Hidalgo M
    J Clin Oncol; 2005 Aug; 23(23):5386-403. PubMed ID: 15983388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
    Mitra AP
    IDrugs; 2009 Jun; 12(6):339-41. PubMed ID: 19517310
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
    Mikalsen T; Gerits N; Moens U
    Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of proteasome inhibitors in oncology and autoimmune diseases.
    Bennett MK; Kirk CJ
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):616-25. PubMed ID: 18729013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Key cancer cell signal transduction pathways as therapeutic targets.
    Bianco R; Melisi D; Ciardiello F; Tortora G
    Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular basis of therapeutic approaches to gastric cancer.
    Wu K; Nie Y; Guo C; Chen Y; Ding J; Fan D
    J Gastroenterol Hepatol; 2009 Jan; 24(1):37-41. PubMed ID: 19196394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis modulators as cancer therapeutics.
    Penn LZ
    Curr Opin Investig Drugs; 2001 May; 2(5):684-92. PubMed ID: 11569948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bcl-2 family members as molecular targets in cancer therapy.
    Marzo I; Naval J
    Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted therapies: a nursing perspective.
    Kay P
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A; Umezawa K; Bonavida B
    Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
    Moretti L; Yang ES; Kim KW; Lu B
    Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
    Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
    Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
    Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule inhibitors in children with malignant gliomas.
    Herrington B; Kieran MW
    Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
    Albo D; Farrow B; Berger DH
    Surg Oncol Clin N Am; 2008 Apr; 17(2):357-76, ix. PubMed ID: 18375357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.